Description

CUROSURF SUSP VIAL is a specialized pharmaceutical product designed for the management of Respiratory Distress Syndrome (RDS) in premature infants. It contains poractant alfa, a natural pulmonary surfactant derived from porcine origin, and is administered intratracheally to replace deficient endogenous surfactant in the lungs.

Composition

This sterile suspension is primarily composed of phospholipids and surfactant-associated proteins, providing a crucial role in reducing alveolar surface tension. The suspension appears white to creamy white and is supplied in ready-to-use vials.

Indications

• Prophylaxis and Treatment: Effective in both the prevention and rescue treatment of RDS in premature infants.
• Meconium Aspiration Syndrome: May reduce respiratory illness severity where indicated.

Dosage Forms

• 1.5 mL Vial: Contains 120 mg of poractant alfa.
• 3 mL Vial: Contains 240 mg of poractant alfa.

Each vial is single-use, with clear glass and color-coded caps for easy identification.

Administration

• Initial Dose: Typically 2.5 mL/kg, with up to two additional doses if needed.
• Methods: Administered via bolus instillation, using techniques such as the INSURE method or Less Invasive Surfactant Administration (LISA).

Proper preparation involves warming the vial to room temperature and gentle mixing by inversion. Continuous monitoring of the infant's cardiorespiratory status is essential during administration.

Precautions

• Contraindications: Hypersensitivity to poractant alfa or its excipients.
• Adverse Effects: Includes transient bradycardia, hypotension, and potential pulmonary complications.

Storage

• Temperature: Store refrigerated at +2°C to +8°C.
• Handling: Protect from light, do not shake, and discard any unused portion after single use.

Legal Classification

CUROSURF SUSP VIAL is classified as a prescription-only medicine, requiring administration by trained healthcare professionals. Its careful handling and precise dosing underscore its critical role in neonatal care, offering significant benefits in improving lung function and reducing respiratory complications in vulnerable infants.